2021
DOI: 10.1093/ndt/gfab136.004
|View full text |Cite
|
Sign up to set email alerts
|

Fc 065predicting Outcomes in Anca Associated Vasculitis: The Complete Scottish Experience

Abstract: Background and Aims Outcomes in ANCA vasculitis remain difficult to predict and therapeutic decision-making can be challenging. We aimed to establish if a renal risk score (RRS) could predict outcomes in this population. Method The Scottish Renal Biopsy Registry is a complete national dataset of all renal biopsies performed in Scotland. Those who had a first renal biopsy between 01/01/2014 and 31/12/2017 with evidence of ANCA… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 1 publication
0
1
0
Order By: Relevance
“…The ARRS was found to have excellent discrimination, and since its publication, multiple retrospective cohort studies have been performed on cumulatively over 2000 patients across three continents. 2539 It was recently incorporated into a proposed tool to identify patients who may benefit from plasma exchange after the results of the plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis trial. 40,41 A recent meta-analysis of 11 ARRS validations with a median number of 130 patients per study (range, 37–252) highlighted the need for larger-scale studies.…”
Section: Introductionmentioning
confidence: 99%
“…The ARRS was found to have excellent discrimination, and since its publication, multiple retrospective cohort studies have been performed on cumulatively over 2000 patients across three continents. 2539 It was recently incorporated into a proposed tool to identify patients who may benefit from plasma exchange after the results of the plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis trial. 40,41 A recent meta-analysis of 11 ARRS validations with a median number of 130 patients per study (range, 37–252) highlighted the need for larger-scale studies.…”
Section: Introductionmentioning
confidence: 99%